VMD Chief Medical Officer William Frazier Buys $18K of Stock

Executive Insider Activity at Viemed Healthcare

When corporate leaders manage their personal holdings, investors often pay attention to see how executives align with company performance. For Viemed Healthcare, Inc. (NasdaqCM: VMD), recent filings show noteworthy moves from key personnel inside the organization. Chief Medical Officer William Frazier added to his connection with the firm by picking up 10,000 shares on June 25, 2026. This purchase totaled $18,100, executing at a price of $1.81 per share.

This transaction followed a busy week of internal trades for the medical device provider. On the exact same day, June 25, 2026, Frazier also parted with 10,000 shares at an average price of $11.72, totaling $117,200. Just a day prior on June 24, 2026, Timothy Smokoff executed a sale of 20,000 shares at an average price of $11.50, which amounted to $229,968. Tracking these separate transactions gives a broader picture of how leadership manages individual stake sizes.

VMD Stock Valuation and Market Context

Shares of Viemed Healthcare recently changed hands at $11.63. The equity moves within a 52-week band defined by a low of $6.05 and a high of $12.61. With a total market capitalization sitting around $337.1 million, the medical device provider trades alongside a trailing price-to-earnings ratio of 24.58 and a forward P/E of 22.13. The company carries a beta of 1.09, pointing to market-level volatility.

Recent Earnings Performance

Operations at Viemed Healthcare continue to generate steady revenue figures across its respiratory disease management and home medical equipment business lines. The company reported annual revenue reaching $301.6 million alongside a revenue growth rate of 23.9%. Profitability metrics show a net margin of 4.81% and a return on equity of 10.45%, with earnings per share resting at $0.36. Market participants can mark their calendars for the next scheduled earnings report, which arrives on November 4, 2026.

Wall Street Analyst Coverage

Analyst firms have updated their outlooks on the medical device sector throughout late summer. On August 6, 2026, Freedom Broker adjusted its stance by issuing a downgrade to a hold rating paired with an 11.00 price target. Later in the month on August 24, 2026, Barrington Research initiated formal coverage on VMD with an outperform rating and a price target of $14.00. Across the broader analyst community, the consensus target sits at a mean price of $12.50 based on two active opinions.

About Viemed Healthcare

Headquartered in Lafayette, Louisiana, Viemed Healthcare operates within the healthcare sector by supplying home medical equipment and post-acute respiratory services throughout the United States. The enterprise specializes in respiratory disease management solutions, supporting patients suffering from chronic obstructive pulmonary disease and other ailments through specialized ventilation devices and sleep apnea therapy products.

Looking Ahead for VMD

Internal trading reports provide a window into executive sentiment, though they represent only one piece of a broader financial puzzle. Investors tracking VMD will likely monitor upcoming earnings results in November alongside ongoing analyst adjustments to gauge how operational growth translates into market value moving forward.